Accendra HealthACH
Recorded

Accendra Health 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration26 minParticipants5

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good evening, and thank you for standing by. Welcome to Accendra Health's third quarter 2026 earnings conference call. Please be advised that today's conference call is being recorded. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I would now like to hand the conference call over to your first speaker today, Will Parrish, Vice President, Corporate Development and Investor Relations.

Will ParrishVP of Corporate Development and Investor Relations

Thank you, operator, and good evening, everyone. I'd like to welcome you to Accendra Health's third quarter earnings call. Our comments on the call will be focused on the financial results of the third quarter of 2026, all of which are included in today's press release. The press release, along with the third quarter 2026 supplemental slides, to which we will refer during the call, are posted on the Investor Relations section of our website. Please note that during this call, we will make forward-looking statements that reflect the current views of Accendra Health about our business, financial performance, and future events. Matters addressed in these statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected or implied here today. Our expectations, beliefs, and projections are expressed in good faith, and we believe there is a reasonable basis for them.

Will ParrishVP of Corporate Development and Investor Relations

However, there can be no assurance that our expectations, beliefs, and projections will result or be achieved. Please refer to our SEC filings for a full description of these risks and uncertainties, including the risk factor section of our annual report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements that we make on this call, in our earnings press release, or in our supplemental slides are as of today, and we undertake no obligation to update these statements as a result of new information or future events, except to the extent required by applicable law. In our discussion today, we will refer to non-GAAP financial measures and believe they might help investors to better understand our performance or business trends. Information about these measures and reconciliations to the most comparable GAAP financial measures are included in our press release.

Will ParrishVP of Corporate Development and Investor Relations

Today, I am joined by Kenny Gardner-Smith, Accendra Health's President and Chief Executive Officer, Jonathan Leon, the company's Chief Financial Officer, and Scott Lloyd, the company's Chief Commercial Officer. I will now turn the call over to Kenny.

Kenny Gardner-SmithPresident and CEO

Kenny? Thank you, Will, and good evening to everyone joining us.

Kenny Gardner-SmithPresident and CEO

It is a pleasure to be speaking with you for the first time as CEO. Accendra is home to leading brands that serve important segments of the home DME market. I have had the privilege of serving on the board for the past several years, which gave me a deep appreciation for the clinical importance of what we do and the strength of our brands and footprint. When the opportunity arose to step into the CEO role, I took it because I believe these assets, combined with a more disciplined operating system, can deliver meaningfully better outcomes for patients, referral sources, and shareholders. My background in growing, optimizing, and scaling specialty healthcare operations and leading turnarounds gives me conviction that most of the issues we face are fixable and largely within our control.

Kenny Gardner-SmithPresident and CEO

I am excited to be here and optimistic about our future. Prior to my official start, I worked closely with the management team and the board on a forward-looking value creation plan. Over the past month, I have spent time digging into the business, listening to leaders and frontline teammates, connecting with key partners, and speaking with our investors. Those conversations, together with the strategy work and the value creation plan, have given myself and the team a clear view of where we stand and what must change. We will not be in a period of prolonged diagnosis. Rather, we are already in the midst of active execution focused on speed to value. I want to acknowledge that in spite of that optimism about our future, we have significantly underperformed expectations in 2026.

Kenny Gardner-SmithPresident and CEO

Before I share my perspective on what has caused the deterioration in performance in 2026 and how we will address it, I will turn it over to John to walk through our Q3 results and balance sheet positioning in more detail.

Jonathan LeonCFO

Thanks, Kenny, and good evening. Turning right to the financial results, the quarter was extremely disappointing, as most of the near-term profit improvement efforts over the last few months did not yield the expected results. On the positive side, we have continued to effectively manage cash flow and expect to have plenty of liquidity for the foreseeable future. Before getting into the specifics of the quarter, please note that any discussion about the financial results and outlook for the company will cover predominantly non-GAAP financial measures. You can find GAAP to non-GAAP financial reconciliations in the press release filed a short time ago and residing on our website at accendrahealth.com.

Jonathan LeonCFO

First, as shown on slide six, third quarter revenue was just under $602 million and was down 1% from the prior year, excluding the impact of the large commercial payer loss earlier this year and the third quarter sale of a non-core asset. This was the first quarter in 2026 in which revenue was down versus the prior year, excluding the impact of the large commercial payer, and the entire organization is focused on reversing this as quickly as possible. Despite attractive year-over-year growth in the very important sleep category, it was not enough to offset ongoing declines in the CGM, respiratory, and wound categories. The soft goods group of ostomy, urology, and incontinence showed growth, although at a much slower rate than they had been growing earlier in the year.

Jonathan LeonCFO

Breaking it down further, excluding the impacts of the terminated contract with a large commercial payer and the sale of a non-core asset, sleep grew over 4%, primarily driven by growth in sleep supplies. However, diabetes declined by nearly 3% as the continuing year-long growth in pumps could not offset drops in CGMs and other diabetes supplies. Also, we did not see enough pickup in respiratory and wound as they fell about 6.5% and 6% respectively, continuing to run well below expectations. Clearly, our efforts to win referrals and maintain patients on therapy are not where they need to be, and as you will hear from Kenny, this is a major focus of our efforts going forward with action already underway.

Jonathan LeonCFO

Contractual allowances, which are an adjustment to gross revenue driven by the long-term collection rate, were again higher than prior year and have not improved to the extent previously expected. However, there has been improvement. Year over year, the third quarter contractual allowance impact was about $4 million smaller than the previous two quarters, coming in at $6 million in favorable versus the prior year, better than the approximately $10 million we cited in the first and second quarters. But collections clearly are still disappointing. The cost of net revenue was 56.6% of net revenue, 280 basis points higher than last year's third quarter, due largely to an almost even split between the category mix change resulting from the first quarter loss of the large commercial payer and the lower collection rate.

Jonathan LeonCFO

However, at 56.6% of net revenue, these costs have remained within 1% point all year and is worth noting to hopefully alleviate concerns about significant supplier price increases. SG&A costs were 41.5% of net revenue, up from 38.1% from the third quarter of 2025, and 180 basis points higher than the second quarter of 2026. The year-over-year change is again largely due to the previously discussed Q1 commercial payer loss and the challenges we continue to face to take out enough costs to offset the lost revenue. Also, throughout the year, we have experienced an increase in business insurance claims driving up SG&A. These issues are all addressable, and we intend to reverse these trends in the months ahead. All of this resulted in Adjusted EBITDA of $47.8 million in the quarter.

Jonathan LeonCFO

Adjusted EBITDA plus non-cash convert to sale write-off expense, less patient service equipment CapEx, was just under $17 million. The details of key drivers are shown in slide eight. A very important detail is shown on that slide. You will see that we have footnoted that $35 million of the year-to-date 2026 patient service equipment CapEx is related to the former large commercial payer contract. As we have said in the past, the CapEx related to that former contract was disproportionately large relative to the Adjusted EBITDA generated. Also, payment terms on much of that equipment are such that the final cash outlays continued into the third quarter of this year. When looking ahead, Adjusted EBITDA less CapEx will benefit meaningfully, and future CapEx will be quite a bit lower in 2027 than 2026. Turning to the balance sheet.

Jonathan LeonCFO

Net debt of $1.73 billion was down $40 million versus December 31st, but was higher by $18 million or 1% from the end of June. Total debt for the year is down $295 million due to the application of the net proceeds from the year-end 2025 divestiture and the balance sheet optimization transactions that closed in June. We are in compliance with our quarterly debt covenants. Moving to the cash flow statement, recognizing that the year has seen significant one-time cash items, on slide nine, we have included a detailed bridge from Adjusted EBITDA to cash flow for operations, which illustrates these one-time items as well as ordinary course items to help reconcile between the two figures.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day